Role of nanoparticles in pancreatic drug delivery: Including a bibliography on Targeted drug delivery

Navni, Sharma*; Vimal, Arora; Gaurav, Joshi; Bhupendra, Gopalbhai, Prajapati; Akshay, Parihar

doi:10.18231/j.ijcaap.2023.019

Article highlight

Article tables

Article images

Article History

Received : 22-03-2023

Accepted : 27-04-2023

Article Indexing

Article Metrics

Citation Managers

Download Citation

Bookmark article

Downlaod Files

Article Access statistics

Viewed: 671

PDF Downloaded: 261

Get Permission Sharma, Arora, Joshi, Prajapati, and Parihar: Role of nanoparticles in pancreatic drug delivery: Including a bibliography on Targeted drug delivery

Journal Information

Journal ID (nlm-ta): Innovative Publication

Journal ID (publisher-id): Innovative Publication

Journal ID (journal_submission_guidelines): https://www.innovativepublication.com/journal/IJCAAP

Title: IP International Journal of Comprehensive and Advanced Pharmacology

ISSN: 2456-9542

Article Information

Date received: 22 March 2023

Date accepted: 27 April 2023

Publication date: 23 May 2023

Volume: 8

Issue: 2

Page: 112

DOI: 10.18231/j.ijcaap.2023.019

Role of nanoparticles in pancreatic drug delivery: Including a bibliography on Targeted drug delivery

[] Navni Sharma[1]

Email: akshay.parihar20@gmail.com

Designation:

Research Scholar

[https://orcid.org/0000-0001-9520-138X] Vimal Arora[2]

Designation:

Professor

[https://orcid.org/0000-0002-1033-0199] Gaurav Joshi[2]

Designation:

Assistant Professor

[https://orcid.org/0000-0001-8242-4541] Bhupendra Gopalbhai Prajapati[3]

Designation:

Professor

[https://orcid.org/0000-0002-9597-2800] Akshay Parihar[4]

Designation:

Assistant Professor

Research Scholar, University Institute of Pharmaceutical Sciences, Chandigarh University, Gharuan Mohali, Punjab India

Dept. of Pharmacy, (UIPS) Chandigarh University Gharuan Mohali, Punjab India

Dept. of Pharmaceutics (Formulation, Development and Characterization), Shree S.K.Patel College of Pharmaceutical Education and Research, Ganpat University Mehsana, Gujarat India

Faculty of Pharmaceutical sciences, The ICFAI University Baddi, Himachal Pradesh India

Abstract

Background: The number of times a publication or an individual author has been discussed in the scientific community is a common metric for measuring their impact. The goal of the bibliometric study was to look at the maximum cited articles in the area of "pancreatic cancer, nanoparticles, targeted ligand, binding, drug delivery and treatment.".

Materials and Methods: The database SCOPUS was used to conduct a computerised literature search. The top 100 articles with the most citations were chosen and studied further

Results: There were 298 citations in the most cited article, with an average of 62 citations per publication. These highly cited publications appeared in 33 journals, with the Journal of Controlled Release leading the pack (27 articles). The United States contributed 53 articles, which originated from 19 different countries. These 100 citations were provided by 85 institutions, with the “Department of Chemical and Biomolecular Engineering” leading the way (4).

Conclusions: The investigation of the top highly cited articles concedes for recognizing significant advances in pancreatic cancer targeted drug delivery study and gives a historical perspective on the advancement of this speciality of cancer research.

Background

Pancreatic cancer is a deadly disease because of its poor prognosis. The chances of the development of this cancer are increasing day by day. Through the physician, scientists got knowledge of advancements through the papers. As the growth of the disease increased, the publication rate also increased. In recent years, there is a huge difference inthe article published count than the previous ones. We received 298 articles by which 15 articles are cited more than 100 times. The main purpose of our analysis is to identify the top citations in the area of pancreatic cancer nanoparticle targeted drug delivery research.1

Materials and Methods

The information was collected using the SCOPUS database, which was launched by Elsevier and generated 298 results. Table 3 lists the top 100 most cited papers in order of citation count. The article with the most citations received 298 while the item with the fewest received only 80. Over 100 citations were found in fourteen papers. The citations of a work from before 2006 that had been cited for 10 years with an average count for each paper was 62. 2

Table 1

The top 100 publications referenced in pancreatic cancer nanoparticles targeted drug - delivery research

Year	Citations of 298 Documents	Number of Papers
<2006	0	0
2006	1	1
2007	8	0
2008	12	4
2009	38	3
2010	76	2
2011	113	7
2012	174	12
2013	249	10
2014	303	19
2015	404	27
2016	560	26
2017	761	36
2018	922	31
2019	1250	39
2020	1736	39
2021	1947	42
Total	8554	298

Table 2

The top 100 publications referenced in pancreatic cancer nanoparticles targeted drug delivery system research

Rank	Reference Number	Number of Citations	Rank	Reference Number	Number of Citations
1	³	280	35	⁴	70
2	⁵	230	36	⁶	68
3	⁷	209	37	⁸	68
4	⁹	157	38	¹⁰	66
5	¹¹	151	39	¹²	64
6	¹³	148	40	¹⁴	64
7	¹⁵	145	41	¹⁶	64
8	¹⁷	142	42	¹⁸	63
9	¹⁹	140	43	²⁰	63
10	²¹	125	44	²²	62
11	²³	124	45	²⁴	61
12	²⁵	112	46	²⁶	60
13	²⁷	111	47	²⁸	58
14	²⁹	109	48	³⁰	57
15	³¹	100	49	³²	57
16	³³	97	50	³⁴	54
17	³⁵	96	51	³⁶	54
18	³⁷	95	52	³⁸	54
19	³⁹	94	53	⁴⁰	54
20	⁴¹	93	54	⁴²	53
21	⁴³	88	55	⁴⁴	52
22	⁴⁵	86	56	⁴⁶	52
23	⁴⁷	86	57	⁴⁸	51
24	⁴⁹	84	58	⁵⁰	50
25	⁵¹	80	59	⁵²	49
26	⁵³	80	60	⁵⁴	49
27	⁵⁵	76	61	⁵⁶	48
28	⁵⁷	75	62	⁵⁸	48
29	⁵⁹	74	63	⁶⁰	48
30	⁶¹	73	64	⁶²	48
31	⁶³	72	65	⁶⁴	47
32	⁶⁵	71	66	⁶⁶	47
33	⁶⁷	71	67	⁶⁸	47
34	⁶⁹	70	68	⁷⁰	47

Table 3

Journals published the top 100 cited papers

Rank	Journals	Number of Article
1	Journal of Controlled Release	27
2	Theranostics	12
3	International Journal of Nanomedicine	10
4	Molecular Pharmaceutics	7
5	Pharmacological Reviews	6
6	Bioconjugate Chemistry	5
7	Advanced Healthcare Materials	3
7	Journal of Nanobiotechnology	3
8	Frontiers in Pharmacology	2
8	Molecular Therapy	2
9	ActaPharmaceuticaSinica B	1
10	Bioconjugate Chemistry	1
11	BioImpacts	1
12	Brazilian Journal of Pharmaceutical Sciences	1
13	ChemMedChem	1
14	Current Cancer Drug Targets	1
15	Current Drug Delivery	1
16	Current Drug Metabolism	1
17	Current Drug Targets	1
18	Current Medicinal Chemistry	1
19	Current Pharmaceutical Design	1
20	Drug Delivery	1
21	Drug Resistance updates	1
22	European Journal of Pharmaceutical Sciences	1
23	European Journal of Pharmaceutics and Biopharmaceutics	1
24	Journal of Clinical Pharmacology	1
25	Journal of Pharmaceutical Analysis	1
26	Journal of Pharmaceutical Sciences	1
27	Molecular Therapy - Nucleic Acids	1
28	Nanomedicine: Nanotechnology, Biology, and Medicine	1
29	Nucleic Acid Therapeutics	1
30	Pharmaceuticals	1
31	Pharmaceutics	1

Table 4

The top 100 referenced articles' countries of origin

Rank	Country	No. of Articles
1	United States	53
2	China	16
3	Germany	5
4	Iran	3
4	Japan	3
4	Poland	3
4	South Korea	3
5	India	2
5	Italy	2
6	Australia	1
6	South Korea	1
6	Estonia	1
6	France	1
6	Mexico	1
6	Netherlands	1
6	Portugal	1
6	Switzerland	1
6	Taiwan	1
6	United Kingdom	1

Table 5

Originating institutions with two or more highly referenced papers

Rank	Institution	Number of Articles
1	Yonsei University	4
2	Department of Biomedical Engineering	3
2	Department of Pharmaceutics	3
3	Cancer Biology Research Centre	2
3	Hampton University	2
3	University of Colorado School of Pharmacy	2
3	Department of Pharmacy	2
3	Department of Surgery	2
3	Department of Technology and Biotechnology of Drugs	2
3	Experimental Pathology and Therapeutics Group	2
3	Laboratory of Cytobiochemistry	2

Results

The SCOPUS database, which was launched by Elsevier, was used to conduct the literature search, which yielded 298 results. Table 3 shows the top 100 most referenced papers ranked by the number of citations. The article with the most citations earned 298 citations, while the article with the least citations saved 80. A total of fourteen articles saved over 100 citations. Each paper received an average of 62 citations. We also looked at the citations of a publication published before 2006 that had been cited for the previous ten years. The results indicate there was no document published and cited before 2006. In the year 2006 number of papers cited: and number of Paper published was 1:1, 2007 (8:0),2008 (12:4),2009 (38:3),2010 (76:2), 2011 (113:7), 2012 (174:12), 2013 (249:10), 2014 (303:19), 2015 (404:27), 2016 (560:26), 2017 (761:36), 2018 (922:31), 2019 (1250:39), 2020 (1736:39), and 2021(1947:42) respectively (Table 2).

The top-cited papers were published in 33 high-impact journals (Table 4), led by the Journal of Controlled Release (27 articles), Theranostics (12 articles), International Journal of Nanomedicine (10 articles), and Molecular Pharmaceutics (7 articles). The top 100 referenced papers came from 19 different nations, with the United States generating 53, China 16 and Germany 5 each (Table 5). These top 100 referenced publications were generated by 85 different universities. Eleven universities generated two or more of the top-cited publications (Table 5), with the Department of Chemical and Biomolecular Engineering leading the way with four articles, followed by the University of Texas with seven, and Harvard University with six (7 articles).

Discussion

A number of aims are served by bibliometric examination of the most frequently cited publications and the journals in which they appear. It acknowledges and emphasises the value of our predecessors' and colleagues' work, highlights major milestones in pancreatic cancer research, and provides helpful historical data. Citation analysis of published research on pancreatic cancer targeted drug delivery gives quantifiable information on authors, nations, and publications, aiding in the finding of high-impact works and journals. This is the first time, as far as we know, that a citation-based analysis of the top citations in pancreatic cancer research has been conducted. Although examining all 100 top citations in detail would be difficult, the top ten may reveal some interesting data.

These 10 notable citations have highlighted significant accomplishments in pancreatic cancer nanoparticle targeted drug delivery research and a variety of related fields throughout the preceding 50 years. The primary paper, written by P. Yingchoncharoen, detailed a lipid medicine delivery system for cancer therapy that might be the most important advancement in medical treatment research in decades. Many articles are still mentioned on a daily basis, and their citation is fully reliable on the passage of time, since the date of publication is a significant determinant in citation. As a consequence, modern works get less citations than older ones. However, no document was cited before 2006, and the years 2015-2021 had the most citations, with 27 and 42, respectively. It illustrates that changes in the previous six years have been more significant. In addition, each year, a huge number of new journals are founded, the number of published papers rises dramatically, and more references are referenced. Three journals namely Theranostics, Journal of Controlled Release, and International Journal of Nanomedicine published 27,12, and 10 papers respectively. This data suggests that these three journals were the most influential in the field of pancreatic cancer nanoparticles targeted drug delivery research. Molecular Pharmaceutics, Pharmacological Reviews, and Bioconjugate Chemistry were also excellent medical journals, with 18 papers published each.

Because this is an important issue and a major concern on a worldwide scale, the publication rate on this topic is consistently increasing in these journals. Another conclusion is that the majority of the most highly reference papers come from the United States. The United States is home to the majority of productive institutions. Because of its big population and funding agencies, the United States has a significant effect on targeted medication delivery for the treatment of pancreatic cancer. The United States government assists and supports the scientific community in their research. There were at least 100 top-cited publications in this review, however, the majority of them were document-type articles. A few of them are not original study papers, but they are classified as opinion pieces for future cancer research, which is why they are often mentioned. The top articles found while searching for "pancreatic cancer nanoparticles tailored ligand binding medication delivery" were mostly about cancer. This article may open up new avenues for medical study and aid in the identification of gaps in pancreatic cancer therapy.

Conclusion

The articles that received the most citations contributed to advancements in the field of pancreatic cancer research. This analysis identifies important advancements in pancreatic cancer and targeted drug delivery research, as well as providing a historical perspective on the history of pancreatic cancer research.

Source of Funding

None.

Conflict of Interest

None.

References

Y Zhang L Quan L Du The 100 top-cited studies in cancer immunotherapyArtificial Cells, Nanomedicine, Biotechnol201947122829210.1080/21691401.2019.1623234

Q Li Y Jiang Top Classic Citations in Pancreatic Cancer ResearchWorld J Surg Oncol201614129810.1186/s12957-016-1061-8

P Cui S Wang Application of Microfluidic Chip Technology in Pharmaceutical Analysis: A ReviewJ Pharm Anal20199423847

A Lowery H Onishko D E Hallahan Z Han Tumor-Targeted Delivery of Liposome-Encapsulated Doxorubicin by Use of a Peptide That Selectively Binds to Irradiated TumorsJ Controlled Release201115011172410.1016/j.jconrel.2010.11.006

N Zhang C Chittasupho C Duangrat TJ Siahaan C Berkland PLGA Nanoparticle-Peptide Conjugate Effectively Targets Intercellular Cell-Adhesion Molecule-1Bioconjug Chem20081911455210.1021/bc700227zhttps://doi.org/10.1021/bc700227z

JL Santiago-Ortiz DV Schaffer Adeno-Associated Virus (AAV) Vectors in Cancer Gene TherapyJ Control Release201624028730110.1016/j.jconrel.2016.01.001

C Szabo A Papapetropoulos International Union of Basic and Clinical Pharmacology. CII: Pharmacological Modulation of H2S Levels: H2S Donors and H2S Biosynthesis InhibitorsPharmacol Rev201769449756410.1124/pr.117.014050

MA Rahman ARMR Amin X Wang JE Zuckerman CHJ Choi B Zhou Systemic Delivery of SiRNA Nanoparticles Targeting RRM2 Suppresses Head and Neck Tumor GrowthJ Control Release201215933849210.1016/j.jconrel.2012.01.045

MM Yallapu SF Othman ET Curtis NA Bauer N Chauhan D Kumar Curcumin-Loaded Magnetic Nanoparticles for Breast Cancer Therapeutics and Imaging ApplicationsInt J Nanomedicine2012717617910.2147/IJN.S29290

MW Ndinguri R Solipuram R P Gambrell S Aggarwal RP Hammer Peptide Targeting of Platinum Anti-Cancer DrugsBioconjug Chem2009201018697810.1021/bc900065r

S Zhu M Niu H O’mary Z Cui Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticlesMol Pharm201310935253010.1021/mp400216r

S Gao D Yang Y Fang X Lin X Jin Q Wang Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer ImmunotherapyTheranostics2019911265110.7150/thno.29431

B Mulloy J Hogwood E Gray R Lever CP Page Pharmacology of Heparin and Related DrugsPharmacol Rev20156817614110.1124/pr.115.011247

K Knoop M Kolokythas K Klutz MJ Willhauck N Wunderlich D Draganovici Image-Guided, Tumor Stroma-Targeted 131 i Therapy of Hepatocellular Cancer after Systemic Mesenchymal Stem Cell-Mediated Nis Gene DeliveryMol Ther201119917041310.1038/mt.2011.93

C Chittasupho SX Xie A Baoum T Yakovleva TJ Siahaan CJ Berkland ICAM-1 Targeting of Doxorubicin-Loaded PLGA Nanoparticles to Lung Epithelial CellsEur J Pharm Sci200937214150

F Wang M Porter A Konstantopoulos P Zhang H Cui Preclinical Development of Drug Delivery Systems for Paclitaxel-Based Cancer ChemotherapyJ Controlled Release20172671001810.1016/j.jconrel.2017.09.026

D Irby C Du F Li Lipid-Drug Conjugate for Enhancing Drug DeliveryMol Pharm201714513253810.1021/acs.molpharmaceut.6b01027

J Xu F Gattacceca M Amiji Biodistribution and Pharmacokinetics of EGFR-Targeted Thiolated Gelatin Nanoparticles Following Systemic Administration in Pancreatic Tumor-Bearing MiceMol Pharm201310520314410.1021/mp400054e

F Alexis P Basto E Levy-Nissenbaum AF Radovic-Moreno L Zhang E Pridgen HER-2-targeted nanoparticle-affibody bioconjugates for cancer therapyChemMedChem200831218394310.1002/cmdc.200800122

MP Melancon RJ Stafford C Li Challenges to Effective Cancer NanotheranosticsJ Controlled Release201216421778210.1016/j.jconrel.2012.07.045

V Sancho A Di Florio TW Moody RT Jensen Bombesin Receptor-Mediated Imaging and Cytotoxicity: Review and Current StatusCurr Drug Deliv2011817913410.2174/156720111793663624

W Wang M Xi X Duan Y Wang FE Kong Delivery of Baicalein and Paclitaxel Using Self-Assembled Nanoparticles: Synergistic Antitumor Effect in Vitro and in VivoInt J Nanomedicine20151037375010.2147/IJN.S80297

J Intra AK Salem Characterization of the Transgene Expression Generated by Branched and Linear Polyethylenimine-Plasmid DNA Nanoparticles in Vitro and after Intraperitoneal Injection in VivoJ Controlled Release200813021293810.1016/j.jconrel.2008.04.014

SKS Kushwaha S Ghoshal AK Rai S Singh Carbon Nanotubes as a Novel Drug Delivery System for Anticancer Therapy: A reviewBraz J Pharm Sci20134946294310.1590/S1984-82502013000400002

JC Sunshine DY Peng JJ Green Uptake and Transfection with Polymeric Nanoparticles Are Dependent on Polymer End-Group Structure, but Largely Independent of Nanoparticle Physical and Chemical PropertiesMol Pharm2012911337583

H Shi X Gao D Li Q Zhang Y Wang Y Zheng A systemic administration of liposomal curcumin inhibits radiation pneumonitis and sensitizes lung carcinoma to radiationInt J Nanomedicine2012726011110.2147/IJN.S31439

VJ Yao S Angelo KS Butler C Theron TL Smith S Marchiò Ligand-Targeted Theranostic Nanomedicines against CancerJ Control Release20162402678610.1016/j.jconrel.2016.01.002

O Mashinchian M Johari-Ahar B Ghaemi M Rashidi J Barar Y Omidi Impacts of Quantum Dots in Molecular Detection and Bioimaging of Cancer Bioimpacts2014431496610.15171/bi.2014.008

JA Ferreira A Peixoto M Neves C Gaiteiro CA Reis YG Assaraf Mechanisms of cisplatin resistance and targeting of cancer stem cells: Adding glycosylation to the equationDrug Resist Updat201624345410.1016/j.drup.2015.11.003

T Sun Y Wang Y Wang J Xu X Zhao S Vangveravong Using Sv119-Gold Nanocage Conjugates to Eradicate Cancer Stem Cells through a Combination of Photothermal and Chemo TherapiesAdv Healthc Mater20143812839110.1002/adhm.201400026

J Park J Park Y Pei J Xu Y Yeo Pharmacokinetics and Biodistribution of Recently-Developed SiRNA NanomedicinesAdv Drug Deliv Rev20161049310910.1016/j.addr.2015.12.004

S Sun E Shang A Ju Y Li Q Wu Q Li Tumor-Targeted Hyaluronic Acid-MPEG Modified Nanostructured Lipid Carriers for Cantharidin Delivery: An in Vivo and in Vitro StudyFitoterapia202115510503310.1016/j.fitote.2021.105033

MS Bhojani M Van Dort A Rehemtulla BD Ross Targeted Imaging and Therapy of Brain Cancer Using Theranostic NanoparticlesMol Pharm2010761921910.1021/mp100298r

S Nordmeier W Ke K A Afonin V Portnoy Exosome mediated delivery of functional nucleic acid nanoparticles (NANPs)Nanomedicine20203010228510.1016/j.nano.2020.102285

A Wei JG Mehtala AK Patri Challenges and Opportunities in the Advancement of NanomedicinesJ Controlled Release201216422364610.1016/j.jconrel.2012.10.007

MA Sandoval BR Sloat P Lansakara DSP Kumar A Rodriguez B L Kiguchi EGFR-Targeted Stearoyl Gemcitabine Nanoparticles Show Enhanced Anti-Tumor ActivityJ Controlled Release201215722879610.1016/j.jconrel.2011.08.015

P Singh G Destito A Schneemann M Manchester Canine Parvovirus-like Particles, a Novel Nanomaterial for Tumor TargetingJ Nanobiotechnol200610.1186/1477-3155-4-2

KJ Isaacson M Martin Jensen NB Subrahmanyam H Ghandehari Matrix-Metalloproteinases as Targets for Controlled Delivery in Cancer: An Analysis of Upregulation and ExpressionJ Controlled Release2017259627510.1016/j.jconrel.2017.01.034

L Xu T Anchordoquy Drug Delivery Trends in Clinical Trials and Translational Medicine: Challenges and Opportunities in the Delivery of Nucleic Acid-Based TherapeuticsJ Pharm Sci20111001385210.1002/jps.22243

PH Wu Y Onodera Y Ichikawa E B Rankin AJ Giaccia Y Watanabe Targeting Integrins with RGD-Conjugated Gold Nanoparticles in Radiotherapy Decreases the Invasive Activity of Breast Cancer CellsInt J Nanomedicine20171250698510.2147/IJN.S137833

J Park Y Choi H Chang W Um JH Ryu IC Kwon Alliance with EPR Effect: Combined Strategies to Improve the EPR Effect in the Tumor MicroenvironmentTheranostics201992680739010.7150/thno.37198

S Chen SK Boda SK Batra X Li J Xie Emerging Roles of Electrospun Nanofibers in Cancer ResearchAdv Healthc Mater201876e170102410.1002/adhm.201701024

G Lin H Zhang L Huang Smart Polymeric Nanoparticles for Cancer Gene DeliveryMol Pharm201512231421Pharmaceutics

M Khoshnejad H Parhiz VV Shuvaev IJ Dmochowski VR Muzykantov Ferritin-Based Drug Delivery Systems: Hybrid Nanocarriers for Vascular ImmunotargetingJ Controlled Release2018282132410.1016/j.jconrel.2018.02.042

J Barar M A Rafi M M Pourseif Y Omidi Blood-Brain Barrier Transport Machineries and Targeted Therapy of Brain DiseasesBioImpacts2016642254810.15171/bi.2016.30https://doi.org/10.15171/bi.2016.30

J Huang F Liu X Han L Zhang Z Hu Q Jiang Nanosonosensitizers for Highly Efficient Sonodynamic Cancer TheranosticsTheranostics201882261789410.7150/thno.29569

V Sanna N Pala G Dessì P Manconi A Mariani S Dedola C Crosio C Iaccarino Single-Step Green Synthesis and Characterization of Gold-Conjugated Polyphenol Nanoparticles with Antioxidant and Biological ActivitiesInt J Nanomedicine20149149355110.2147/IJN.S70648

R Gilabert-Oriol A Weng B Von Mallinckrodt MF Melzig H Fuchs M Thakur Immunotoxins Constructed with Ribosome-Inactivating Proteins and Their Enhancers: A Lethal Cocktail with Tumor Specific EfficacyCurr Pharm Design20142042658464310.2174/1381612820666140826153913

D Liu D T Auguste Cancer Targeted Therapeutics: From Molecules to Drug Delivery VehiclesJournal of Controlled Release2015219632643

G Battogtokh YY Cho JY Lee HS Lee HC Kang Mitochondrial-Targeting Anticancer Agent Conjugates and Nanocarrier Systems for Cancer TreatmentFront Pharmacol2018910.3389/fphar.2018.00922

M Toporkiewicz J Meissner L Matusewicz A Czogalla AF Sikorski Toward a Magic or Imaginary Bullet? Ligands for Drug Targeting to Cancer Cells: Principles, Hopes, and ChallengesInt Jf Nanomedicine201510139941410.2147/IJN.S74514

MK Gurka D Pender P Chuong BL Fouts A Sobelov MW Mcnally Identification of Pancreatic Tumors in Vivo with Ligand-Targeted, PH Responsive Mesoporous Silica Nanoparticles by Multispectral Optoacoustic TomographyJ Controlled Release201623160710.1016/j.jconrel.2015.12.055

J Liu J Liu H Xu Y Zhang L Chu Q Liu Novel Tumor-Targeting, Self-Assembling Peptide Nanofiber as a Carrier for Effective Curcumin DeliveryInt J Nanomedicine20139119720710.2147/IJN.S55875

DN Pandya R Hantgan MM Budzevich ND Kock DL Morse I Batista Preliminary Therapy Evaluation of 225Ac-DOTA-c (RGDyK) Demonstrates That Cerenkov Radiation Derived from 225Ac Daughter Decay Can Be Detected by Optical Imaging for in Vivo Tumor Visualization.Theranostics20166569870910.7150/thno.14338

K Numata J Hamasaki B Subramanian DL Kaplan Gene Delivery Mediated by Recombinant Silk Proteins Containing Cationic and Cell Binding MotifsJ Controlled Release2010146113643

D Porciani L Tedeschi L Marchetti L Citti V Piazza F Beltram Aptamer-Mediated Codelivery of Doxorubicin and NF-ΚB Decoy Enhances Chemosensitivity of Pancreatic Tumor CellsMol Ther - Nucleic Acids201544e23510.1038/mtna.2015.9

J Despanie J P Dhandhukia S F Hamm-Alvarez J A Mackay Elastin-like Polypeptides: Therapeutic Applications for an Emerging Class of NanomedicinesJournal of Controlled Release201624093108

P S Thakuri C Liu G D Luker H Tavana Biomaterials-Based Approaches to Tumor Spheroid and Organoid ModelingAdv Healthcare Mater201876e170098010.1002/adhm.201700980

J Lu W Zhao Y Huang H Liu R Marquez R B Gibbs J Li R Venkataramanan L Xu S Li S Li S Li Targeted Delivery of Doxorubicin by Folic Acid-Decorated Dual Functional NanocarrierMolecular Pharmaceutics2015111141644178

J Adijanto M I Naash Nanoparticle-Based Technologies for Retinal Gene TherapyEur J Pharm Biopharmaceutics2015953536710.1016/j.ejpb.2014.12.028

MO Abdalla P Karna H K Sajja H Mao C Yates T Turner Enhanced Noscapine Delivery Using UPAR-Targeted Optical-MR Imaging Trackable Nanoparticles for Prostate Cancer TherapyJ Controlled Release2011149331422

SH Tseng MY Chou IM Chu Cetuximab-Conjugated Iron Oxide Nanoparticles for Cancer Imaging and TherapyInt J Nanomedicine20151036638510.2147/IJN.S80134

Y Zhang JW Chan A Moretti KE Uhrich Designing Polymers with Sugar-Based Advantages for Bioactive Delivery ApplicationsJ Controlled Release20152193556810.1016/j.jconrel.2015.09.053

P Ray MA Cheek ML Sharaf N Li AD Ellington BA Sullenger Aptamer-Mediated Delivery of Chemotherapy to Pancreatic Cancer CellsNucleic Acid Therapeutics201222529530510.1089/nat.2012.0353

P Yingchoncharoen DS Kalinowski DR Richardson Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is yet to ComePharmacol Rev20166837018710.1124/pr.115.012070

T Stylianopoulos R K Jain Design considerations for nanotherapeutics in oncologyNanomedicine2015118189390710.1016/j.nano.2015.07.015

A Shergalis A Bankhead U Luesakul N Muangsin N Neamati Current Challenges and Opportunities in Treating GlioblastomasPharmacol Rev20187034124510.1124/pr.117.014944

T Yang B Li S Qi Y Liu Y Gai P Ye Co-Delivery of Doxorubicin and Bmil SiRNA by Folate Receptor Targeted Liposomes Exhibits Enhanced Anti-Tumor Effects in Vitro and in VivoTheranostics2014411109611110.7150/thno.9423

CJ Gannon CR Patra R Bhattacharya P Mukherjee SA Curley Intracellular Gold Nanoparticles Enhance Non-Invasive Radiofrequency Thermal Destruction of Human Gastrointestinal Cancer CellsJ Nanobiotechnol200810.1186/1477-3155-6-2

J Lee DG Jo D Park HY Chung MP Mattson Adaptive Cellular Stress Pathways as Therapeutic Targets of Dietary Phytochemicals: Focus on the Nervous SystemPharmacol Rev20146638156810.1124/pr.113.007757

Keywords

Categories:

Subject: Original Research Article

Keywords:

Keywords

Pancreatic Cancer

nanoparticles

Targeted Drug delivery

Global publications

Bibliometric analysis

TopCitations

jats-html.xsl

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.